Table 3.

Treatment‐emergent adverse events for Torsades de Pointes standardized MedDRA queries

MedDRA v. 12.1, n (%) preferred term	Isavuconazole (n = 257)	Voriconazole (n = 259)
Patients with ≥ 1 Torsades de Pointes TEAE	15 (5.8)	19 (7.3)
Syncope	7 (2.7)	2 (0.8)
Loss of consciousness	3 (1.2)	0
Cardio‐respiratory arrest	2 (0.8)	2 (0.8)
Electrocardiogram QT prolonged	2 (0.8)	8 (3.1)
Cardiac arrest	1 (0.4)	6 (2.3)
Sudden cardiac death	0	1 (0.4)
Ventricular tachycardia	0	2 (0.8)

MedDRA, medical dictionary for regulatory activities; TEAE, treatment‐emergent adverse event.